AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2023

Jun 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2023-06-28

Reporting Person: Goff Brian (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-28	Common stock	M	25528	—	Acquired	25528	Direct
2023-06-30	Common stock	S	11449	$28.36	Disposed	14079	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-28	Performance share units	$	M	25528	Disposed		Common stock (25528)	Direct

Footnotes

F1: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units.

F2: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

F3: The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.